Growth factor-eluting hydrogels for management of corneal defects.


Journal

Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 24 05 2020
revised: 27 08 2020
accepted: 03 12 2020
entrez: 6 2 2021
pubmed: 7 2 2021
medline: 13 5 2021
Statut: ppublish

Résumé

With 1.5-2.0 million new cases annually worldwide, corneal injury represents a common cause of vision loss, often from irreversible scarring due to surface corneal defects. In this study, we assessed the use of hepatocyte growth factor (HGF) loaded into an in situ photopolymerizable transparent gelatin-based hydrogel for the management of corneal defects. In vitro release kinetics showed that, in regard to the total amount of HGF released over a month, 55 ± 11% was released during the first 24 h, followed by a slow release profile for up to one month. The effect of HGF was assessed using an ex vivo model of pig corneal defect. After three days of organ culture, epithelial defects were found to be completely healed for 89% of the corneas treated with HGF, compared to only 11% of the corneas that had fully re-epithelialized when treated with the hydrogel without HGF. The thickness of the epithelial layer was found to be significantly higher for the HGF-treated group compared to the group treated with hydrogel without HGF (p = 0.0012). Finally, histological and immunostaining assessments demonstrated a better stratification and adhesion of the epithelial layer in the presence of HGF. These results suggest that the HGF-loaded hydrogel system represents a promising solution for the treatment of persistent corneal defects at risk of scarring.

Identifiants

pubmed: 33545916
pii: S0928-4931(20)33709-7
doi: 10.1016/j.msec.2020.111790
pmc: PMC7867677
mid: NIHMS1656185
pii:
doi:

Substances chimiques

Hydrogels 0
Hepatocyte Growth Factor 67256-21-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111790

Subventions

Organisme : NIBIB NIH HHS
ID : R01 EB023052
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL140618
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Références

Sci Transl Med. 2017 Oct 4;9(410):
pubmed: 28978753
Stem Cells Int. 2012;2012:915160
pubmed: 23093979
Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):300-7
pubmed: 24327573
Biomaterials. 2010 Jun;31(16):4573-82
pubmed: 20206988
ACS Appl Mater Interfaces. 2018 Apr 25;10(16):13283-13292
pubmed: 29620862
Int J Nanomedicine. 2016 Sep 23;11:4875-4890
pubmed: 27729786
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5907-5917
pubmed: 29164231
Stem Cell Reports. 2016 Oct 11;7(4):583-590
pubmed: 27693426
Biomaterials. 2015 Mar;45:56-63
pubmed: 25662495
J Control Release. 2014 Oct 28;192:82-94
pubmed: 24998940
J Biomed Mater Res B Appl Biomater. 2014 Nov;102(8):1700-10
pubmed: 24664907
Cell Transplant. 2015;24(3):541-59
pubmed: 25668102
PLoS One. 2015 Nov 13;10(11):e0142099
pubmed: 26566050
J Cardiovasc Transl Res. 2011 Oct;4(5):559-74
pubmed: 21656074
Exp Eye Res. 2018 Jan;166:49-55
pubmed: 29024692
Adv Healthc Mater. 2018 Aug;7(16):e1701434
pubmed: 29845780
Sci Rep. 2016 Aug 09;6:31036
pubmed: 27503340
Sci Adv. 2019 Mar 20;5(3):eaav1281
pubmed: 30906864
Fortschr Ophthalmol. 1990;87(4):378-81
pubmed: 2210567
Saudi J Ophthalmol. 2014 Jul;28(3):168-72
pubmed: 25278792
Biofabrication. 2017 Aug 21;9(4):044101
pubmed: 28770808
Macromol Biosci. 2009 Dec 8;9(12):1194-201
pubmed: 19890886
Nat Rev Mater. 2016 Dec;1(12):
pubmed: 29657852
Am J Ophthalmol. 1992 Nov 15;114(5):630-2
pubmed: 1443028
Biomaterials. 2010 May;31(13):3596-603
pubmed: 20153045
Mol Ther. 2017 Aug 2;25(8):1881-1888
pubmed: 28502469
PLoS One. 2012;7(11):e50980
pubmed: 23226440
Acta Biomater. 2017 Jan 15;48:110-119
pubmed: 27773752
PLoS One. 2020 Jan 13;15(1):e0227732
pubmed: 31929592
J Control Release. 2014 Aug 10;187:1-13
pubmed: 24852096

Auteurs

Clotilde Jumelle (C)

Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, United States.

Ehsan Shirzaei Sani (ES)

Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, United States.

Yukako Taketani (Y)

Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, United States.

Ann Yung (A)

Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, United States.

Fanny Gantin (F)

Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, United States.

Sunil K Chauhan (SK)

Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, United States.

Nasim Annabi (N)

Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, CA 90095, United States. Electronic address: nannabi@ucla.edu.

Reza Dana (R)

Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, United States. Electronic address: reza_dana@meei.harvard.edu.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH